摘要
背景:卵巢癌是导致妇科恶性肿瘤的主要死亡原因。 晚期诊断和高转移倾向和耐药性往往导致复发和不良结局。 抗血管生成被认为是复发性卵巢癌的有希望的治疗策略。 抗VEGF体,贝伐单抗,是具有活性和可耐受毒性的血管生成抑制剂。目的:阐明贝伐珠单抗治疗复发性卵巢癌的疗效和副作用。 方法:审查已发表的临床试验结果。 结果:最近的II期研究表明,贝伐单抗单一疗法或与常规或其他抗血管生成化疗试剂组合可能对复发(铂敏感和抗药性)卵巢癌有效。 另外,两个III期随机试验得出了类似的结论,即在铂敏感或抵抗性卵巢癌中,将贝伐珠单抗加入化疗可以改善无进展生存期。 尽管贝伐珠单抗在复发性卵巢癌患者中被普遍认可为良好耐受的药物,但肿瘤学家已经意识到与胃肠穿孔有关的重大风险。 结论:贝伐单抗单独使用或与其他化学疗法组合使用对治疗复发性卵巢癌有效和耐受。
关键词: 贝伐单抗,化疗,疗效,卵巢癌,复发,安全性,化疗。
Current Drug Targets
Title:The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer
Volume: 18 Issue: 10
关键词: 贝伐单抗,化疗,疗效,卵巢癌,复发,安全性,化疗。
摘要: Background: Ovarian cancer is the leading cause of deaths attributable to gynecologic malignancies. Late diagnosis and a high tendency of metastasis and drug resistance often lead to recurrence and poor outcomes. Anti-angiogenesis is considered a promising therapeutic strategy for recurrent ovarian cancers. Anti-VEGF body, bevacizumab, is an angiogenesis inhibitor with demonstrated activity and tolerable toxicity.
Objective: To elucidate the benefits and side effects of bevacizumab for the therapy of recurrent ovarian cancer. Methods: Reviewed the results of published clinical trials. Results: Recent Phase II studies indicated that bevacizumab monotherapy or in combination with conventional or other anti-angiogenic chemotherapy reagents could be effective for recurrent (platinum- sensitive and -resistant) ovarian cancers. Additionally, two phase III randomized trials reached similar conclusions that in either platinum-sensitive or -resistant ovarian cancers, adding bevacizumab to chemotherapy can improve progression-free survival. Despite the general recognition of bevacizumab as a well-tolerated drug in recurrent ovarian cancer patients, oncologists have become aware of the significant risks associated with gastrointestinal perforation. Conclusion: Bevacizumab used alone or combined with other chemotherapy reagents is efficacious and tolerable in the treatment of recurrent ovarian cancer.Export Options
About this article
Cite this article as:
The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer, Current Drug Targets 2017; 18 (10) . https://dx.doi.org/10.2174/1389450117666160502150237
DOI https://dx.doi.org/10.2174/1389450117666160502150237 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Interplay Between Inflammation and Oxidative Stress in Carcinogenesis
Current Molecular Medicine Is the Modulation of Autophagy the Future in the Treatment of Neurodegenerative Diseases?
Current Topics in Medicinal Chemistry Glioma Targeting and Anti-glioma Effect of Interleukin 13 Peptide and RGD Peptide Dual Functionalized Nanoparticles
Current Pharmaceutical Biotechnology Current Insights of Inhibitors of p38 Mitogen-Activated Protein Kinase in Inflammation
Medicinal Chemistry PREFACE [Hot topic: Current Concepts in Assisted Reproduction and Fertility Preservation (Part II) (Guest Editors: Sajal Gupta and Ashok Agarwal)]
Current Women`s Health Reviews Catalytic Reactions in Fluorinated Phosphonates Synthesis
Current Green Chemistry Diffuse Large B-Cell Lymphoma Presenting as an Anterior Chest Wall Mass: A Case Report and Literature Review
Current Respiratory Medicine Reviews Denosumab: The Era of Targeted Therapies in Bone Metastatic Diseases
Current Cancer Drug Targets The Tribbles-1 Protein in Humans: Roles and Functions in Health and Disease
Current Molecular Medicine Differential Splicing, Disease and Drug Targets
Infectious Disorders - Drug Targets Telomere Maintenance as Therapeutic Target in Embryonal Tumours
Anti-Cancer Agents in Medicinal Chemistry Intracellular Proton Pumps as Targets in Chemotherapy: V-ATPases and Cancer
Current Pharmaceutical Design Role of Solid Lipid Nanoparticles for the Delivery of Lipophilic Drugs and Herbal Medicines in the Treatment of Pulmonary Hypertension
Pharmaceutical Nanotechnology Sol-Gel Chemistry in Biosensing Devices of Electrical Transduction: Application to CEA Cancer Biomarker
Current Topics in Medicinal Chemistry HIV-1 Vpr: Enhancing Sensitivity of Tumors to Apoptosis
Current Drug Delivery Anti-Genes: siRNA, Ribozymes and Antisense
Current Pharmaceutical Biotechnology Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its Anticancer Activity
Current Medicinal Chemistry Cellular FLICE-Like Inhibitory Protein (C-FLIP): A Novel Target for Cancer Therapy
Current Cancer Drug Targets Cancer Pharmacogenomics: Germline DNA, Tumor DNA, or Both?
Current Pharmacogenomics Current Status and Perspectives in the Development of Camptothecins
Current Pharmaceutical Design